A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF ALISERTIB COMBINED WITH IRINOTECAN AND TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA.

被引：0
|
作者：
Kudgus, R. A. [1 ]
Fox, E. [2 ]
McGovern, R. M. [1 ]
Moorthy, G. [2 ]
Marachelian, A. [3 ]
DuBois, S. G. [4 ]
Reid, J. M. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[3] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-031
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [41] Phase II single-arm study of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma
    Grill, J.
    Perek, D.
    Sanchez de Toledo-Codina, J.
    Madero, L.
    Estlin, E.
    Canete, A.
    Icher, C.
    Breazna, A.
    Geoerger, B.
    Cisar, L.
    Hargrave, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors
    Jonathan Metts
    Brittany Harrington
    Emad Salman
    Scott M. Bradfield
    Jennifer Flanary
    Maua Mosha
    Ernest Amankwah
    Stacie Stapleton
    Child's Nervous System, 2022, 38 : 919 - 928
  • [43] Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma: A BEACON-Neuroblastoma biomarker study.
    Moreno, Lucas
    Weston, Rebekah
    Viprey, Virginie
    Tchirkov, Andrei
    Corrias, Maria
    Lammens, Tim
    Gray, Juliet
    Owens, Cormac
    Laidler, Jennifer
    Gambart, Marion
    Castel, Victoria
    Van Eijkelenburg, Natasha
    Nysom, Karsten
    Laureys, Genevieve
    Castellano, Aurora
    Gerber, Nicolas U.
    Ladenstein, Ruth Lydia
    Couanet, Dominique Valteau
    Wheatley, Keith
    Burchill, Susan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors
    Metts, Jonathan
    Harrington, Brittany
    Salman, Emad
    Bradfield, Scott M.
    Flanary, Jennifer
    Mosha, Maua
    Amankwah, Ernest
    Stapleton, Stacie
    CHILDS NERVOUS SYSTEM, 2022, 38 (05) : 919 - 928
  • [45] A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG)
    Vassal, Gilles
    Giammarile, Francesco
    Brooks, Mariel
    Geoerger, Birgit
    Couanet, Dominique
    Michon, Jean
    Stockdale, Elizabeth
    Schell, Matthias
    Geoffray, Anne
    Gentet, Jean-Claude
    Pichon, Fabienne
    Rubie, Herve
    Cisar, Laura
    Assadourian, Sylvie
    Morland, Bruce
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (16) : 2453 - 2460
  • [46] Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study.
    DuBois, S. G.
    Chesler, L.
    Groshen, S. G.
    Hawkins, R.
    Goodarzian, F.
    Yanik, G. A.
    Stewart, C. F.
    Mosse, Y. P.
    Maris, J. M.
    Villablanca, J.
    Matthay, K. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACONNeuroblastoma randomized phase 2 trial A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.
    Moreno, Lucas
    Moroz, Veronica
    Owens, Cormac
    Laidler, Jennifer
    Valteau-Couanet, Dominique
    Gambart, Marion
    Castel, Victoria
    Van Eijkelenburg, Natasha
    Castellano, Aurora
    Nysom, Karsten
    Gerber, Nicolas U.
    Laureys, Genevieve
    Ladenstein, Ruth Lydia
    Makin, Guy
    Vaidya, Sucheta
    Thebaud, Estelle
    Kearns, Pamela
    Pearson, Andrew D. J.
    Wheatley, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Olaparib Associated with Irinotecan in Children and Adolescents "with Relapsed or Refractory Tumors" - ARM D of the European AcSe-ESMART Trial
    Gatz, S.
    Rubino, J.
    Rossoni, C.
    Andre, N.
    Aerts, I.
    Thebaud, E.
    Nebchi, S.
    Marchais, A.
    Rondof, W.
    Huebschmann, D.
    Mortimer, P. G.
    Paoletti, X.
    Vassal, G.
    Geoerger, B.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S69 - S69
  • [49] A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.
    DuBois, Steven G.
    Kremer, Jill D.
    De Wilde, Bram
    Jacobsen, Chad
    Aerts, Isabelle
    Mosse, Yael P.
    Maris, John M.
    Lithio, Andrew
    Gosberg, Andreas
    Banks, C. L.
    Tate, Courtney
    Dowless, Michele
    Gong, Xueqian
    Stancato, Louis
    Bell-McGuinn, Katherine M.
    Park, Julie R.
    Pearson, Andrew Dj
    Marachelian, Araz
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.
    Marachelian, Araz
    Hogarty, Michael D.
    Flynn, Andrea
    Liu, Kangning
    Gerner, Eugene W.
    Bruckheimer, Elizabeth
    Shamirian, Anasheh
    Hasenauer, Charlotte
    Norris, Murray
    Haber, Michelle
    Groshen, Susan G.
    Ziegler, David Simon
    Matthay, Katherine K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345